Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artequick versus Coartem for uncomplicated falciparum malaria
ChiCTR1900025860Phase 4Not yet recruiting
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Artequick and lumefantrine in Malaria (2 arms), sponsored by Guangzhou University of Chinese Medicine. Primary endpoints: Plasmodium density, Leukocyte count and 9 more. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
Artequicklumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on ChiCTR1900025860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025860.